title: Prognostication in primary myelofibrosis.
abstract: Primary myelofibrosis (PMF) is a Philadelphia chromosome-negative chronic myeloproliferative neoplasm usually affecting elderly people. Median survival currently approaches 6 years, with a few patients surviving more than 20 years but others dying soon after diagnosis. In 10% to 20% of patients, PMF evolves into acute leukemia. Conventional treatment is merely palliative and does not prolong survival. The only chance for cure is allogeneic hemopoietic stem-cell transplantation (allo-HSCT), which is associated with high morbidity and mortality. Introduction of less aggressive forms of allo-HSCT and the prospect of molecular-targeted therapies has renewed interest in prognostication in PMF. The most important prognostic factors are anemia, age over 65 years, constitutional symptoms, leukocytosis, blood blasts, and some cytogenetic abnormalities. These factors have recently been systematized into an International Prognostic Scoring System (IPSS) and further refined in a dynamic IPSS (DIPSS), useful at any time over the disease course, as well as a DIPSS-plus model including karyotypic information.
authors.affiliation: Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Villarroel 170, Barcelona, Spain. fcervan@clinic.ub.es
authors.forename: Francisco
authors.initials: F
authors.lastname: Cervantes
authors.forename: Arturo
authors.initials: A
authors.lastname: Pereira
mesh_terms: D000367:Age Factors; D000740:Anemia / Q000175:diagnosis; D002471:Cell Transformation, Neoplastic; D003582:Cytogenetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000473:pathology; D010976:Platelet Count; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D018570:Risk Assessment
references.citation: Blood. 1996 Aug 1;88(3):1013-8
references.pmid: 8704209
references.citation: J Clin Oncol. 2011 Apr 1;29(10):1356-63
references.pmid: 21300928
references.citation: Br J Haematol. 1997 Jul;98(1):96-102
references.pmid: 9233570
references.citation: Blood. 2001 Dec 1;98(12):3249-55
references.pmid: 11719361
references.citation: Curr Opin Hematol. 2011 Mar;18(2):117-23
references.pmid: 21307773
references.citation: Cancer. 2007 May 15;109(10):2083-8
references.pmid: 17407134
references.citation: Leukemia. 2011 Dec;25(12):1834-9
references.pmid: 21691276
references.citation: Blood Rev. 2011 Mar;25(2):53-63
references.pmid: 21095048
references.citation: N Engl J Med. 2000 Apr 27;342(17):1255-65
references.pmid: 10781623
references.citation: Br J Haematol. 1988 Dec;70(4):397-401
references.pmid: 3219290
references.citation: Blood. 2007 Dec 1;110(12):4030-6
references.pmid: 17712047
references.citation: Blood. 2010 Jun 3;115(22):4350-5
references.pmid: 20308601
references.citation: Br J Haematol. 1997 Jun;97(3):635-40
references.pmid: 9207412
references.citation: Br J Haematol. 2001 Jun;113(3):763-71
references.pmid: 11380468
references.citation: Eur J Haematol. 2009 Oct;83(4):328-33
references.pmid: 19549278
references.citation: Leukemia. 2008 Apr;22(4):756-61
references.pmid: 18216871
references.citation: Am J Hematol. 2011 Mar;86(3):245-50
references.pmid: 21328437
references.citation: Br J Haematol. 1998 Aug;102(3):684-90
references.pmid: 9722294
references.citation: Cancer. 2008 Jun 15;112(12):2726-32
references.pmid: 18404742
references.citation: Leukemia. 2008 May;22(5):905-14
references.pmid: 18385755
references.citation: Haematologica. 2003 Nov;88(11):1204-12
references.pmid: 14607748
references.citation: Eur J Haematol. 1990 Feb;44(2):95-9
references.pmid: 2318300
references.citation: Blood. 2000 Nov 15;96(10):3374-80
references.pmid: 11071630
references.citation: Am J Hematol. 2010 Jan;85(1):14-7
references.pmid: 20029953
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5587-93
references.pmid: 19786661
references.citation: Blood. 2011 Mar 31;117(13):3494-504
references.pmid: 21200024
references.citation: Haematologica. 2011 Jan;96(1):167-70
references.pmid: 20884708
references.citation: Blood. 2009 Mar 26;113(13):2895-901
references.pmid: 18988864
references.citation: Blood. 2011 May 26;117(21):5612-5
references.pmid: 21450904
references.citation: Blood. 2011 Aug 18;118(7):1723-35
references.pmid: 21653328
references.citation: Blood. 2010 Jan 21;115(3):496-9
references.pmid: 19901264
references.citation: Blood. 2010 Mar 4;115(9):1703-8
references.pmid: 20008785
references.citation: Blood. 2009 Apr 30;113(18):4171-8
references.pmid: 19131547
references.citation: J Clin Oncol. 2011 Feb 1;29(4):392-7
references.pmid: 21149668
references.citation: Blood. 1998 May 15;91(10):3630-6
references.pmid: 9572998
references.citation: Br J Haematol. 1990 May;75(1):4-9
references.pmid: 2375922
references.citation: Am J Hematol. 2009 May;84(5):265-7
references.pmid: 19396855
references.citation: Blood. 2009 Aug 20;114(8):1477-83
references.pmid: 19549988
references.citation: Blood. 2009 Jul 30;114(5):937-51
references.pmid: 19357394
references.citation: Blood. 2006 Mar 1;107(5):2098-100
references.pmid: 16293597
references.citation: Leukemia. 2010 Jun;24(6):1128-38
references.pmid: 20428194
references.citation: Br J Haematol. 2005 Jan;128(1):42-8
references.pmid: 15606548
references.citation: Leukemia. 2011 Jan;25(1):82-8
references.pmid: 20944670
references.citation: Mayo Clin Proc. 2009 Dec;84(12):1114-9
references.pmid: 19955247